Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3438-3444

  Di Lorenzo, Giuseppe ^a   Tortora, Giampaolo ^a   D'Armiento, Francesco P ^a   De Rosa, Gaetano ^a   Staibano, Stefania ^a   Autorino, Riccardo ^a   D'Armiento, Massimo ^a   De Laurentiis, Michele ^a   De Placido, Sabino ^a   Catalano, Giuseppe ^a   Bianco, A Raffaele ^a   Ciardiello, Fortunato ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE MARKER; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; BIOSYNTHESIS; DISEASE COURSE; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROSTATE TUMOR; RECURRENT DISEASE; TIME;

ANDROGENS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECURRENCE; TIME FACTORS;

EID: 0036847724     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Auclerc, G., Antoine, E. C., Cajfinger, F., Brunet-Pommeyrol, A., Agazia, C., and Khayat, D. Management of advanced prostate cancer. Oncologist, 5: 36-44, 2000.
2. Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Verner, P. M., Coppin, C. M., and Murphy, K. C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomised trial with palliative end points. J. Clin. Oncol., 17: 1654-1663, 1996.
3. Petrylak, D. P. Chemotherapy for advanced hormone refractory prostate cancer. Urology, 54: 30-35, 1999.
4. Ware, J. L. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev., 12: 287-301, 1993.
5. Steiner, M. S. Role of peptide growth factors in the prostate: A review. Urology, 42: 99-110, 1993.
6. Russell, P. F., Bennett, S., and Stricker, P. Growth factor involvement in progression of prostate cancer. Clin. Chem., 44: 705-723, 1998.
7. Tillotson, J. K., and Rose, D. P. Density-dependent regulation of epidermal growth factor receptor expression in DU145 human prostate cancer cells. Prostate, 19: 53-61, 1991.
8. Traish, A. M., and Wotiz, H. H. Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology, 121: 1461-1467, 1987.
9. Hofer, D. R., Sherwood, E. R., Bromberg, W. D., Mendelsohn, J., Lee, C., and Kozlowski, J. M. The functional role of transforming growth factor α as an autocrine growth factor in androgen-independent human prostatic carcinoma. Cancer Res., 51: 2780-2785, 1991.
10. Scher, H. I., Sarkis, A., Reuter, V., Cohen, D., Netto, G., Petrylak, D., Lianes, P., Fuks, Z., Mendelsohn, J., and Cordon-Cardo, C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms. Clin. Cancer Res., 1: 545-550, 1995.
11. Wells, A. Molecules in focus: EGFR receptor. Int. J. Biochem. Cell Biol., 31: 637-643, 1999.
12. Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19: 183-232, 1995.
13. De Placido, S., Carlomagno, C., De Laurentiis, M., and Bianco, A. R. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. Breast Cancer Res. Treat., 52: 55-64, 1998.
14. Sadasivan, R. Morgan, R., Jennings, S., Austenfeld, M., Van Veldhuizen, P., Stephens, R., and Noble, M. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J. Urol., 150: 126-131, 1993.
15. Gu, K., Mes-Masson, A. M., Gauthier, J., and Saad, F. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett., 99: 185-189, 1996.
16. Myers, R. B., Srivastava, S., Oelschlager, D. K., and Grizzle, W. E. Expression of p160erbB-3 and p185 erbb-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst. (Bethesda), 86: 1140-1145, 1994.
17. Ross, J. S., Sheehan, C. E., Hayner-Buchan, A. M., Ambros, R. A., Kallakury, B. V. Kaufman, R. P., Jr., Fisher, H. A., Rifkin, M. D., and Muraca, P. J. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer (Phila.), 79: 2162-2170, 1997.
18. Kuhn, E. J., Kurnot, R. A., Sesterhenn, I. A., Chang, E. H., and Moul, J. W. Expression of the c-erbB-2 (Her-2/neu) oncoprotein in human prostatic carcinoma. J. Urol., 150: 1427-1433, 1993.
19. Fox, S. B., Persad, R. A., Coleman, N., Day, C. A., Silcocks, P. B., and Collins, C. C. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. Br. J. Urol., 74: 214-220, 1994.
20. Giri, D. K., Wadhwa, S. N., Upadhaya, S. N., and Talwar, G. P. Expression of NEU/HER2 oncoprotein (p185 neu) in prostate tumors: An immunohistochemical study. Prostate, 23: 329-336, 1993.
21. Morote, J., de Torres, I., Caceres, C., Vallejo, C., Schwartz, S., Jr., and Reventos, J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. Int. J. Cancer, 84: 421-425, 1999.
22. Mydlo, J. H., Kral, J. G., Volpe, M., Axotis, C., Macchia, R. J., and Pertschuk, L. P. An analysis of microvessel density, androgen receptor, p53 and Her2/neu expression and Gleason score in prostate cancer: Preliminary results and therapeutic implications. Eur. Urol., 34: 426-432, 1998.
23. Osman, I., Scher, H. I., Drobnjak, M., Verbel, D., Morris, M., Agus, D., Ross, J. S., and Cordon-Cardo, C. Her-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin. Cancer Res., 7: 2643-2647, 2001.
24. Signoretti, S., Montironi, R., Manola, J., Altimari, A., Tam, C., Bubley, G., Balk, S., Thomas, G., Kaplan, I., Hlatky, L., Hahnfeldt, P., Kantoff, P., and Loda, M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. (Bethesda), 92: 1918-1925, 2000.
25. Shy, Y., Brands, F. H., Chatterjee, S., Feng, A. C., Groshen, S., Schewe, J., Lieskovsky, G., and Cote, R. J. Her-2/NEU expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease. J. Urol., 166: 1514-1519, 2001.
26. Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., Hussain, M., Kaplan, R., Myers, C., Oh, W., Petrylak, D. P., Reed, E., Roth, B., Sartor, O., Scher, H., Simons, J., Sinibaldi, V., Small, E. J., Smith, M. R., Trump, D. L., Vollmer, R., and Wilding, G. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. J. Clin. Oncol., 17: 3461-3467, 1999.
27. Jacobs, T. W., Gown, A. M., Yazijj, H., Barnes, M. J., and Schnitt, S. J. Specificity of HercepTest in determining HER-2/neu status of breast cancer using the United States Food and Drug Administration Approved Scoring System. J. Clin. Oncol., 17: 1983-1987, 1999.
28. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
29. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163-170, 1996.
30. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
31. Culing, Z., Hobisch, A., Hittmair, A., Peterziel, H., Cato, A. C., and Bartsch, G. Expression, structure and function of androgen receptor in advanced prostate cancer. Prostate, 35: 63-70, 1998.
32. Jenster, G. Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. J. Pathol., 191: 227-228, 2000.
33. Nazareth, L. V., and Weigel, N. L. Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem., 271: 19900-19907, 1996.
34. Ye, D., Mendelsohn, J., and Fan, Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27 and costimulate proliferation of MDA PCA 2a and MDA PCA 2b prostate cancer cells. Clin. Cancer Res., 5: 2171-2177, 1999.
35. Yeh, S., Lin, H. K., Kang, H. Y., Thin, T. H., Lin, M. F., and Chang, C. From HER2-neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci., USA, 96: 5458-5463, 1999.
36. Abreu-Martin, M. T., Chari, A., Palladino, A. A., Craft, N. A., and Sawyers, C. L. Mitogen activated protein kinase 1 activates androgen receptor dependent transcription and apoptosis in prostate cancer. Mol. Cell. Biol., 19: 5143-5154, 1999.
37. Barton, J., Blackledge, G., and Wakeling, A. Growth factors and their receptors: New targets for prostate cancer therapy. Urology, 58: 114-122, 2001.
38. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med., 5: 280-285, 1999.
39. Gil-Diez de Medina, S., Salomon, L. Colombel, M., Abbou, C. C., Bellot, J., Thiery, J. P., Radvanyi, F., van der Kwast, T. H., and Chopin, D. K. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum. Pathol., 29: 1005-1012, 1998.
40. Mendelsohn, J., and Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene, 19: 6550-6565, 2000.
41. Ciardiello, F., and Tortora, G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin. Cancer Res., 7: 2958-2970, 2001.
42. McClelland, R. A., Barrow, D., Madden, T. A., Dutkowski, C. M., Pamment, J., Knowlden, J. M., Gee, J. M., and Nicholson, R. I. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex). Endocrinology, 142: 2776-2788, 2001.
43. Sirotnak, F. M., She, Y., Lee, F., and Scher, H. I. Studies with CWR22 xenograft models in nude mice suggest that ZD1839 ("Iressa") may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics. A542, 2001.
44. Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Ciardiello, F., Salomon, D. S., and Menard, S. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab on human breast cancer cell growth. Proc. Am. Assoc. Cancer Res., 42: 774, 2001.
45. Moulder, S. L., Yakes, F. M., Bianco, R., and Arteaga, C. L. A rationale for the use of small molecule EGF receptor tyrosine kinase inhibitors against HER2/neu (erbB-2) overexpressing breast tumor cells. Proc. Am. Assoc. Cancer Res., 42: 853, 2001.
46. Anido, J., Albanell, J., Rojo, F., Codony-Servat, J., Arribas, J., and Baselga, J. Inhibition by ZD1839 (Iressa) of epidermal growth factor (EGF) and heregulin induced signaling pathways in human breast cancer cells. Proc. Am. Soc. Clin. Oncol., 21: 429a, 2001.